Jane Pritchett Henderson

Jane Pritchett Henderson has more than 28 years of experience in health care life sciences with a unique combination of extensive investment banking, corporate biopharmaceutical senior management, and board director experience, making her a trusted advisor to numerous companies. Jane is currently the Chief Financial Officer of Adagio Therapeutics. Prior to joining Adagio, she served as Chief Financial Officer at Turnstone Biologics, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, and Chief Financial and Business Officer at Kolltan Pharmaceuticals until its sale to Celldex Therapeutics. Previously, Jane served in various financial and business development leadership roles at ISTA Pharmaceuticals, Axerion Pharmaceuticals, and Panacos Pharmaceuticals. Jane has an extensive healthcare investment banking background in addition to her industry experience, including execution of over 95 M&A, advisory, and financing transactions over a nearly 20-year career at HSBC, CIBC, Lehman Brothers, and Salomon Brothers, collectively. Jane currently serves on the Board of Directors of IVERIC Bio (formerly Ophthotech) and Sesen Bio (formerly Eleven Biotherapeutics). Jane holds a BS from Duke University.